Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-Current Debt (2020)

Vistagen Therapeutics' Non-Current Debt history spans 2 years, with the latest figure at $87300.0 for Q3 2020.

  • For Q3 2020, Non-Current Debt changed N/A year-over-year to $87300.0; the TTM value through Sep 2020 reached $87300.0, changed N/A, while the annual FY2016 figure was $27200.0, N/A changed from the prior year.
  • Non-Current Debt for Q3 2020 was $87300.0 at Vistagen Therapeutics, down from $124700.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $124700.0 in Q2 2020 and bottomed at $27200.0 in Q1 2016.